Industry Themes

MP Group: Outlook on Microphysiological Systems (MPS) – The future of pre-clinical R&D

Outlook on ‘Microphysiological Systems (MPS) – The future of pre-clinical R&D’ that outlines the challenges with traditional drug testing, alternatives to the traditional methods, and the current and future perspective on MPS technologies. With a ~90% failure rate of drugs in clinical trials, the biopharma R&D continues to operate with substandard efficiency. The traditional drug testing methods (in-vitro and in-vivo) often fail to translate into clinical observations. Therefore, there is a high unmet need to develop in-vitro systems offering improved…

Continue Reading

MP Group- Natural Language Processing: An AI tool to cash-in the ‘big-text’ in life sciences

2020 saw several milestones for the use of Artificial Intelligence (AI) in pharma, including the entry of the first AI-designed molecule in clinical trials. While digital pathology and chemistry/small molecule-oriented AI applications have already found their way into mainstream news, we would like to share with you an outlook on Natural language processing (NLP) - An AI tool to cash-in the ‘big-text’ in life sciences. Pharma has seen an explosion in terms of data. PubMed has more than 30 million citations, clinicaltrialgov has…

Continue Reading

MP Outlook – 2021 and Beyond

At the threshold of this New Year, we are pleased to share the ‘MP Outlook – 2021 and Beyond’ (link to the presentation) where we present our analyses on some of the high-impact areas potentially reshaping BioPharma industry, especially from the learnings due to the pandemic. Some of the key highlights of the presentation are –   BioPharma can no longer afford to spend a decade and a billion dollar in getting a drug to the market. Integration of AI-based platform…

Continue Reading

MP Group – AI toolkit for early-stage drug discovery

Early this year, we shared an outlook giving an overview of the role of Artificial Intelligence in Drug Discovery. Through our conversations with several global pharma and biotechs, we realized that, while the enthusiasm around the potential of AI is high, a shadow of skepticism looms over. A common theme in our dialogs was on explaining the advantages of AI-based interventions over the traditional methods and what to expect out of AI-based platforms. To help build a deeper perspective on AI…

Continue Reading

Next Generation CROs – Differentiated technologies today that will pay-off tomorrow

Historically, CROs have grown by building the scales for the services that pharma cos and biotechs wanted to outsource due to a number of reasons, from reducing the overheads, to cost-effective operations, to downsizing the headcount for effective management, etc. As a result, operational efficiency, large scales and past experiences have been the key value propositions, with relatively lesser focus on differentiated offerings, of course with a few exceptions. However, with BioPharma now riding on a wave of innovative technologies,…

Continue Reading

MP Group – Outlook of Protein Formulation Technologies – Opportunities for IV to subQ Conversion

Currently,~80% of biologics are administered intravenously due to high doses and challenges associated with high concentration protein formulation development – viscosity, stability including aggregation and volume. As a result, patients are tethered to IV infusion set-up for hours, few times a month often in a clinic or hospital, adding significant cost. Subcutaneous delivery enhances patient compliance and convenience, while significantly reducing the cost associated with hospitalization. Only a handful of technologies have attempted to address the protein formulation challenge, that…

Continue Reading

MP Group – Overview of Biobetters: IV to SC formulation conversion for patient compliance, healthcare savings, and market differentiation

The key highlights of the presentation are: Biobetters are an improved version of a biologic and provide better efficacy, safety and patient compliance while reducing the overall burden on healthcarePotential opportunity for Biosimilars company for marketplace differentiation and evasion of patent dance, and for Innovators to extend product lifecycle and delay biosimilars threatIntravenous (IV) to subcutaneous (SC) conversion is one of the most prudent strategies to address the unmet need of patient compliance while reducing the overall healthcare costsThe current…

Continue Reading

Japan Biosimilars: Landscape Today, Outlook Tomorrow – ‘Biosame’ entry, uninterrupted supply and companies’ strong front-end footprint requirements make it a distinct market

- After a decade, JP Biosimilar guideline’s first revision expected in FY2020 –Demonstrate Chuikyo need of biosimilar tool to curb healthcare cost - Biosimilars uptake varies as per each opportunity, Remicade BS vs. Rituxan BS- Two poles of the curve - A few skipping NHI listing due to manufacturing issues associated with constantsupply need, Japanese CDMO imminent to seal  this local need Since 2009, 25 biosimilars of 12 originator products are approved in Japan and have yielded mixed performances and…

Continue Reading

MP Group – Global Biosimilars Outlook, 2019

Year 2019 has been a pivotal year for biosimilars and it is our pleasure to share with you the Global Biosimilars Outlook, 2019, whichcovers in-depth analyses of biosimilars landscape across major geographies (EU, US, Japan, China and India) and presents ideas on how to move ahead in order to achieve global leadership in what we believe will be $40B market by 2025. EU Biosimilar Landscape: The most evolved market currently at a tipping point A matured biosimilar market, although with heterogeneous penetration across the member statesBetter prescriber incentives and multiple winning tenders will not…

Continue Reading

MP Group – Biosimilars Landscape – China and India

As you are exploring biosimilar opportunities, we would be delighted to share our insights to help you advance your strategy. Our active work has enabled us to develop an in depth understanding of the global biosimilar opportunity, and many of our forecasts of the past decade are now being realized. In fact, that is why the title of the attached slide deck is “Creating a global biosimilars leadership - Combining complementary strengths of China and India” (Click here to download) Global…

Continue Reading
Close Menu